BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38214069)

  • 1. Recurrent Aortic Thromboembolism Associated With
    Bukhari S; Saati A; Abuhalimeh B; Ouma G
    J Investig Med High Impact Case Rep; 2024; 12():23247096231224366. PubMed ID: 38214069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
    Batta K; Bossenbroek HM; Pemmaraju N; Wilks DP; Chasty R; Dennis M; Milne P; Collin M; Beird HC; Taylor J; Patnaik MM; Cargo CA; Somervaille TCP; Wiseman DH
    Leukemia; 2021 Nov; 35(11):3299-3303. PubMed ID: 33833384
    [No Abstract]   [Full Text] [Related]  

  • 3. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
    Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia.
    Garcia-Gisbert N; Arenillas L; Roman-Bravo D; Rodriguez-Sevilla JJ; Fernández-Rodríguez C; Garcia-Avila S; Velez P; Gibert J; Fernández-Ibarrondo L; Salar A; Florensa L; Bellosillo B; Ferrer A; Calvo X
    Leukemia; 2022 Dec; 36(12):2922-2926. PubMed ID: 36273104
    [No Abstract]   [Full Text] [Related]  

  • 9. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
    Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
    Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
    Gurney M; Greipp PT; Gliem T; Knudson R; Al-Kali A; Gangat N; Lasho T; Mangaonkar AA; Finke CM; Patnaik MM
    Leuk Res; 2023 Nov; 134():107391. PubMed ID: 37769597
    [No Abstract]   [Full Text] [Related]  

  • 12. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The upregulation of NLRP3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (TET2) contributed to diabetic neuropathic pain in mice.
    Chen W; Wang X; Sun Q; Zhang Y; Liu J; Hu T; Wu W; Wei C; Liu M; Ding Y; Liu D; Chong Y; Wang P; Zhu H; Cui W; Zhang J; Li Q; Yang F
    J Neuroinflammation; 2022 Dec; 19(1):302. PubMed ID: 36527131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
    Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
    Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
    PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Quang VT; Podvin B; Desterke C; Tarfi S; Barathon Q; Badaoui B; Freynet N; Parinet V; Leclerc M; Maury S; Solary E; Selimoglu-Buet D; Duployez N; Wagner-Ballon O; Sloma I
    Haematologica; 2023 Nov; 108(11):3135-3141. PubMed ID: 37102610
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.